Applied Therapeutics (APLT) Price & Analysis

Compare

793 Followers

APLT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.30 - $10.62

Previous CloseN/A

Volume3.84M

Average Volume (3M)932.79K

Market Cap

$70.95M

Enterprise Value$17.32M

Total Cash (Recent Filing)$30.42M

Total Debt (Recent Filing)$2.60M

Price to Earnings (P/E)―

Beta1.29

Next Earnings

Nov 06, 2025

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding144,012,130

10 Day Avg. Volume940,553

30 Day Avg. Volume932,792

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.24

Enterprise Value/Revenue141.96

Enterprise Value/Gross Profit-279.34

Enterprise Value/Ebitda-0.16

Forecast

1Y Price Target

$2.25

Price Target Upside359.18% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical DataThere may be objective MRI analyses that suggest disease progression is slowing between 12 and 24 months.

Operational StrategyNew management has been focused on executing on their operational, regulatory, and clinical goals, positioning APLT in a stronger position across these strategies.

Regulatory ProgressAPLT believes they are positioned for forward momentum as they engage with the FDA to discuss the latest data generated in sorbitol dehydrogenase (SORD) deficiency.

Bears Say

Clinical Trial ResultsTreatment with govorestat did not lead to significant improvement in the 10-meter walk-run test, nor was there a significant improvement in the Charcot-Marie-Tooth Functional Outcome Measure.

Financial PerformanceApplied reported a net loss of $21.8 million in the first quarter.

Regulatory ChallengesThe company requested a meeting with the Office of Scientific Investigations to discuss the matter but was not granted a meeting.

Applied Therapeutics News

Applied Therapeutics reports Q2 EPS (15c), consensus (16c)

Cash and cash equivalents totaled $30.4M as of June 30, 2025 vs. $79.4M at December 31, 2024.”The first...

20d ago

APLT

Applied Therapeutics Announces New Equity Offering Agreement

The latest update is out from Applied Therapeutics ( ($APLT) ). On August 29, 2025, Applied Therapeutics, Inc....

4d ago

APLT

Strategic Positioning and Growth Potential: Joseph Schwartz’s Buy Rating on Applied Therapeutics

Analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on Applied Therapeutics, with a price target of...

15d ago

APLT

Applied Therapeutics Granted Nasdaq Compliance Extension

The latest announcement is out from Applied Therapeutics ( ($APLT) ). Applied Therapeutics, Inc. received a notification from...

20d ago

APLT

Applied Therapeutics Advances Pipeline Amid Financial Challenges

Applied Therapeutics ( ($APLT) ) has released its Q2 earnings. Here is a breakdown of the information Applied...

20d ago

APLT

Applied Therapeutics Faces Nasdaq Listing Challenge

Applied Therapeutics ( ($APLT) ) has issued an announcement. On February 7, 2025, Applied Therapeutics received a notification...

22d ago

APLT

Applied Therapeutics Announces New Chief Medical Officer

Applied Therapeutics ( ($APLT) ) just unveiled an announcement. On June 17, 2025, Applied Therapeutics announced the departure...

3M ago

APLT

Applied Therapeutics CMO Riccardo Perfetti to depart, Evan Bailey to succeed

Applied Therapeutics (APLT) announced the promotions of Evan Bailey to chief medical officer, effective June 15 and Dottie...

3M ago

APLT

Applied Therapeutics Elects New Director at Annual Meeting

The latest update is out from Applied Therapeutics ( ($APLT) ). At the 2025 Annual Meeting of Stockholders...

3M ago

APLT

Hold Rating for Applied Therapeutics Amid Mixed Results from Govorestat Trial

William Blair analyst Sami Corwin has reiterated their neutral stance on APLT stock, giving a Hold rating on...

4M ago

APLT

Applied announces INSPIRE Phase 2/3 trial primary endpoint not significant

Applied Therapeutics (APLT) presented full 12-month clinical results and new topline data from 18 and 24 months from...

4M ago

APLT

Strategic Advancements and Regulatory Progress Drive Buy Rating for Applied Therapeutics

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Applied Therapeutics (APLT – Research Report) on May...

4M ago

APLT

Applied Therapeutics Reports Q1 2025 Financial Results

Applied Therapeutics ( ($APLT) ) has released its Q1 earnings. Here is a breakdown of the information Applied...

4M ago

APLT

Applied Therapeutics reports Q1 EPS (15c), consensus (18c)

Cash and cash equivalents and short-term investments totaled $50.8M as of March 31, compared with $79.4M at December...

4M ago

APLT

APLT FAQ

What was Applied Therapeutics Inc’s price range in the past 12 months?

Applied Therapeutics Inc lowest stock price was $0.29 and its highest was $10.62 in the past 12 months.

What is Applied Therapeutics Inc’s market cap?

Applied Therapeutics Inc’s market cap is $70.95M.

When is Applied Therapeutics Inc’s upcoming earnings report date?

Applied Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 64 days.

How were Applied Therapeutics Inc’s earnings last quarter?

Applied Therapeutics Inc released its earnings results on Aug 13, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.165 by $0.015.

Is Applied Therapeutics Inc overvalued?

According to Wall Street analysts Applied Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Applied Therapeutics Inc pay dividends?

Applied Therapeutics Inc does not currently pay dividends.

What is Applied Therapeutics Inc’s EPS estimate?

Applied Therapeutics Inc’s EPS estimate is -0.14.

How many shares outstanding does Applied Therapeutics Inc have?

Applied Therapeutics Inc has 144,012,130 shares outstanding.

What happened to Applied Therapeutics Inc’s price movement after its last earnings report?

Applied Therapeutics Inc reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.165. Following the earnings report the stock price went up 4.444%.

Which hedge fund is a major shareholder of Applied Therapeutics Inc?

Currently, no hedge funds are holding shares in APLT

Applied Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-150.82%

Trailing 12-Months

Asset Growth

-70.78%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Applied Therapeutics Inc

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Applied Therapeutics (APLT) Earnings & Revenues

Historic Earnings Reports

APLT Stock 12 Month Forecast

Average Price Target

$2.25

▲(359.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.44,0.6369230769230769,0.8338461538461539,1.0307692307692307,1.2276923076923076,1.4246153846153846,1.6215384615384614,1.8184615384615384,2.0153846153846153,2.2123076923076925,2.4092307692307693,2.606153846153846,2.803076923076923,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.44,0.5792307692307692,0.7184615384615385,0.8576923076923078,0.996923076923077,1.1361538461538463,1.2753846153846153,1.4146153846153846,1.5538461538461539,1.6930769230769231,1.8323076923076924,1.9715384615384617,2.1107692307692307,{"y":2.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.44,0.5215384615384615,0.6030769230769231,0.6846153846153846,0.7661538461538462,0.8476923076923077,0.9292307692307693,1.0107692307692309,1.0923076923076924,1.173846153846154,1.2553846153846155,1.336923076923077,1.4184615384615384,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.07,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.33,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.44,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.66,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.34,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.39,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.41,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >